A GLP1R gene variant and sex influence the response to semaglutide treatment in patients with severe obesity
Authors' conclusion
The rs6923761G→A gene variant and sex profoundly affect weight loss in response to semaglutide in patients with severe obesity.
Study context
- Population
- Patients with grade 3 obesity (BMI ≥ 40 kg/m²) treated with semaglutide 2.4 mg weekly for over 4 months, March 2023 to July 2024
- Participants
- 112 patients
- Exposure
- GLP1R rs6923761 AA homozygotes vs carriers of at least one G allele
- AAn = 9
- Outcome
- Weight loss kinetics (% per month) on semaglutide by rs6923761 genotype
Methodological detailsprospective genotyping
- Prospective genotyping
Main finding
As reported in the abstract
Weight loss kinetics
P = 0.03
Observational data: associations, not effects.
Further findings
| Outcome | Values | P value |
|---|---|---|
| Weight loss rate by sex and genotypeWomen homozygous for A allele vs Men carrying G allele · more than double with women homozygous for A allele | Women homozygous for A allele mean 1.89% (SD 0.75%) per month · Men carrying G allele mean 0.7% (SD 0.7%) per month | P = 0.0009 |
| Nonresponders by sex and genotype | Men carrying G allele 56% |
rs6923761 genotype frequency
- AA
- 9 out of 112 patients (8%)
- GA
- 42 out of 112 (37.5%)
- GG
- 61 out of 112 (54.5%)
Predictors of weight loss (multivariate analysis)
- rs6923761G→A and sex were independent predictors of weight loss
Nonresponders by sex and genotype
- No woman homozygous for the A allele was a nonresponder
Original publication
A GLP1R gene variant and sex influence the response to semaglutide treatment in patients with severe obesity. Obesity (Silver Spring). Published 19 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →